Honeynaps Co.

Seoul, South Korea All South Korea companies → — Founded 2015

Medical Device / Hardware Specialty-Focused AI

Series B — $16.2 million

Claim this company

Products

SOMNUM

HoneyNaps

Clinical Decision Support & Reference

SOMNUM is an AI-enabled medical software tool by Honeynaps Co., Ltd. that provides comprehensive sleep analysis to aid in the diagnosis and management of sleep disorders.

See all 1 product →

About Honeynaps Co.

Honeynaps Co. is a South Korean digital health company specializing in AI-driven sleep diagnostics, sleep disorder analytics, and next-generation sleep healthcare solutions. The company develops technologies that enhance access, efficiency, and clinical accuracy in sleep medicine through artificial intelligence and scalable healthcare platforms. Their flagship product, SOMNUM, is an AI-powered software that analyzes polysomnography (PSG) data to identify sleep stages and key events like apnea, hypopnea, and arousals, providing rapid sleep disorder diagnoses within minutes. SOMNUM has received U.S. FDA approval, with the latest version (V3.0) expanding capabilities for automated analysis and classification of sleep-disordered breathing into Obstructive, Central, and Mixed Sleep Apnea.

For physicians, Honeynaps’ technology offers a significant advancement in sleep medicine by automating and accelerating the diagnostic process, which traditionally requires manual review taking several hours per case. SOMNUM’s deep learning-based AI analyzes large volumes of multi-channel/time series biosignals in real-time, aiming for high accuracy and transparency. The company is also developing next-generation AI technologies and digital biomarkers, including Hypoxic Burden (HB), Arousal Burden (AB), and Ventilatory Burden (VB), to enable more comprehensive evaluation of disease severity and associated health risks. Beyond sleep disorder diagnosis, Honeynaps plans to expand its AI applications to other critical areas such as cardiovascular disease, dementia, and Parkinson’s disease.

Focus Areas

AI-driven sleep diagnostics sleep disorder analytics digital sleep medicine bio-signal monitoring disease prediction algorithms digital therapeutics

Business Intelligence

Key Investors	Industrial Bank of Korea, Hi Investment Partners, QUAD Investment Management
Partnerships	Philips Korea, Megazone Cloud, major university hospitals across the U.S.
Acquisitions	unknown
Technology	Deep learning-based AI, real-time analysis of multi-channel/time series biosignals, eXplainable Medical AI (XAI) technology, cloud-native platform
FDA Clearances	2 cleared products (estimated)

What Physicians Need to Know

AI-driven Sleep Diagnostics (SOMNUMu2122)

Honeynaps' flagship product, SOMNUMu2122, is an FDA-cleared AI-based software that automates the analysis of polysomnography (PSG) data. It identifies sleep stages and key events like apnea, hypopnea, and arousals, significantly reducing manual scoring time from hours to minutes. SOMNUM V3.0 further expands capabilities for automated analysis and classification of obstructive, central, and mixed sleep apnea with over 97% agreement rates. It utilizes deep learning-based AI for real-time analysis of multi-channel, time-series biosignal data.

Sleep Disorder Analytics

The company provides advanced analytics for sleep disorders, moving beyond traditional composite indices to offer event-level classification for more accurate assessment of sleep-disordered breathing severity. Their platform supports objective, reproducible, and consistent sleep analysis across multiple study sites, aligning with American Academy of Sleep Medicine (AASM) guidelines.

Digital Sleep Medicine (SOMNUM Medella)

Honeynaps offers SOMNUM Medella, a second-generation digital therapeutic for insomnia. This solution leverages their proprietary contactless sleep data monitoring system, 'SOMNUM Scanning,' to create personalized treatment modules for insomnia, aiming to maximize patient compliance and treatment outcomes.

Bio-signal Monitoring

Honeynaps has developed an intelligent bio-signals monitoring platform, HoneyCube, which aims to collect and analyze bio-signals 24 hours a day. This includes data such as body temperature, heart rate, breathing, and movement during sleep to detect abnormal symptoms early. They are also developing a next-generation wireless polysomnography system using patch-based skin sensors to capture comprehensive physiological signals without cables.

Disease Prediction Algorithms

Beyond diagnosis, Honeynaps is developing algorithms to predict diseases using collected bio-signal data, with the goal of enabling preventive measures, customized diets, and early intervention. This includes the potential to detect or predict cardiovascular, neurological, and muscular diseases.

Digital Therapeutics

Honeynaps is actively involved in digital therapeutics, particularly for insomnia with SOMNUM Medella. These are software medical devices (SaMDs) designed to prevent, manage, or treat disorders, often based on cognitive-behavioral treatments.

Physician Tip

Honeynaps' solutions, particularly SOMNUMu2122, offer physicians a significant advantage by automating and accelerating the analysis of complex PSG data, reducing scoring time from several hours to mere minutes. The FDA clearance of SOMNUMu2122 (including V3.0 for sleep-disordered breathing classification) provides regulatory validation and assurance of the AI algorithm's clinical performance and reliability. The platform's ability to provide event-level classification and distinguish different apnea subtypes can lead to more accurate assessments and tailored treatment plans. Furthermore, their development of a wireless PSG system and contactless monitoring aims to improve patient comfort and enable broader use in both hospital and home settings. The company's focus on explainable AI (XAI) in SOMNUMu2122 enhances transparency and reliability, which can be crucial for physician trust and understanding of AI-driven diagnoses. Their expansion into CRO services also means they can support clinical trials for a wider range of therapeutic areas where sleep is a critical biomarker.

Honeynaps' SOMNUMu2122 Cloud offers a HIPAA-compliant, web-based platform for large-scale sleep data analysis, allowing users to upload EDF files from PSG devices for automated AI analysis and report generation without software installation. The company is also developing encoding/decoding software that supports international standard interfaces like HL7, DICOM, and ISO to ensure information compatibility with other medical fields. They are actively pursuing collaborations with leading US hospitals and sleep centers, and engaging in joint research and clinical partnerships with global pharmaceutical and medical device companies.

At a glance

Founded 2015

HQ Seoul, South Korea · South Korea

Team size 11-50

CEO Lee Young-jun

Funding Series B — $16.2 million

FDA clearances 2 (estimated)

Products 1

Products by Honeynaps Co.

1 product in the directory

SOMNUM

HoneyNaps

Clinical Decision Support & Reference

SOMNUM is an AI-enabled medical software tool by Honeynaps Co., Ltd. that provides comprehensive sleep analysis to aid in the diagnosis and management of sleep disorders.

Reviews & Opinions

No web reviews on file yet for Honeynaps Co.. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Honeynaps Co..

Loading videos...

Videos load interactively. If none appear, search YouTube for Honeynaps Co. →

View all on YouTube

Press & Coverage

U.S. Food & Drug Administration (FDA)

Honeynaps Co., Ltd. FDA 510(k) Premarket Notification for Somnum (v.1.1.2.)

Honeynaps Co., Ltd. received FDA 510(k) clearance for its Somnum (v.1.1.2.) software, an electroencephalograph intended as an aid for the diagnosis of sleep and respiratory-related sleep disorders. The software is for analysis, display, summarization, and report generation of digital data collected by monitoring devices.

2023-08

U.S. Food & Drug Administration (FDA)

Honeynaps co,. Ltd. FDA 510(k) Premarket Notification for Somnum (somnum)

Honeynaps Co., Ltd. received another FDA 510(k) clearance for its Somnum (somnum) software, an AI-enabled program for the diagnosis of sleep and respiratory-related sleep disorders, including automatic scoring using AI/ML algorithms.

2026-06

Taylor & Francis Online (Digital Health)

AIu2011Enhanced Smartwatch AHI Estimation and AIu2011Scored Polysomnography for Obstructive Sleep Apnea: Realu2011World Validation

This study, published in Digital Health, utilized Honeynaps Co., Ltd.'s FDA 510(k)-cleared Somnum software (K223922) for AI-based PSG analysis in a real-world validation of AI-enhanced smartwatch AHI estimation for obstructive sleep apnea. The software analyzes physiological data from polysomnography records for sleep stages, respiratory events, arousal events, and leg movement events.

2025-09

Digital Health (via PMC)

A deep learning algorithm model to automatically score and grade obstructive sleep apnea in adult polysomnography

This research paper details the use of SOMNUM, an AI diagnostic program developed by Honeynaps Co. Ltd., to automatically assess and rate sleep-related respiratory episodes in adult polysomnography. The study demonstrated high sensitivity and specificity of the deep learning algorithm across all OSA severities.

2024-10

ReportLinker

Software As A Medical Device (SaMD) Market Size Report 2026-2030

Honeynaps Co. Ltd. is highlighted for receiving USFDA approval in September 2023 for its SOMNUM software, a sleep disease analysis software that uses deep learning-based AI to perform real-time analysis of various sleep biosignals. This is presented as a key development in the Software As A Medical Device (SaMD) market.

2026-02

PMC (Journal of Cardiovascular Translational Research)

Cardiovascular Disease, Sleep-Disordered Breathing, and Artificial Intelligence: From Neutral Trials to Precision Sleep Cardiology

Honeynaps Co., Korea, is mentioned in this medical journal article for its SOMNUM software (2023), which uses deep learning-based automated algorithms trained on PSG data to detect sleep stages, arousal, respiratory, and limb movement events for home screening of sleep apnea.

2026-03

SLEEP (Oxford Academic)

0444 A Digital Therapy Based on Real-time Sleep Sensing Data

Honeynaps Co., Ltd. is actively working on a new digital Cognitive Behavioral Therapy for Insomnia (CBT-I) that incorporates a real-time sleep sensing device to improve patient compliance and overcome the limitations of traditional CBT-I.

2024-04

Journal of Clinical Medicine (MDPI)

Demographic and Sleep Study Factors Influencing Short-Term Adherence to Positive Airway Pressure Therapy in Obstructive Sleep Apnea

An author from Honeynaps Research and Development Center, Honeynaps Co., Ltd., contributed to this peer-reviewed article discussing factors influencing short-term adherence to Positive Airway Pressure therapy in Obstructive Sleep Apnea.

2025-06

Frequently Asked Questions

What specific AI-driven sleep diagnostic capabilities does Honeynaps Co. offer, and how do they integrate with existing clinical workflows?

Honeynaps Co. utilizes advanced AI algorithms to analyze bio-signals for comprehensive sleep diagnostics, identifying various sleep disorders with high accuracy. Our solutions are designed for seamless integration with current Electronic Health Record (EHR) systems and clinical platforms, providing actionable insights directly to physicians and healthcare administrators.

How does Honeynaps Co.'s digital sleep medicine platform contribute to disease prediction and personalized treatment plans?

Our platform leverages machine learning to analyze sleep patterns and bio-signals, identifying early indicators of potential health issues beyond traditional sleep disorders. This enables proactive disease prediction and facilitates the development of personalized digital therapeutic interventions tailored to individual patient needs, improving overall health outcomes.

What are Honeynaps Co.'s primary digital therapeutic products, and what evidence supports their efficacy and patient compliance?

Honeynaps Co. offers a suite of digital therapeutics focused on various sleep disorders, including CBT-I programs and personalized sleep hygiene interventions. Our products are backed by clinical trials demonstrating significant improvements in sleep quality and patient compliance, with ongoing research to further validate their long-term efficacy.

Can you provide details on Honeynaps Co.'s pricing structure, technical support, and training for healthcare providers?

Our pricing models are flexible, offering subscription-based services and per-patient licensing options to accommodate diverse healthcare settings. We provide comprehensive technical support, including 24/7 assistance and dedicated account managers, along with extensive training programs for healthcare providers to ensure optimal utilization of our platforms.

What is Honeynaps Co.'s approach to data security, patient privacy, and regulatory compliance (e.g., HIPAA, GDPR) for its bio-signal monitoring and analytics?

Honeynaps Co. prioritizes data security and patient privacy, adhering to stringent regulatory standards such as HIPAA and GDPR. We employ robust encryption protocols, secure data storage, and anonymization techniques to protect sensitive patient information throughout our bio-signal monitoring and analytics processes.

What partnerships does Honeynaps Co. have with other healthcare organizations or research institutions, and what is the company's long-term stability and vision?

Honeynaps Co. has established strategic partnerships with leading academic medical centers and research institutions to advance sleep science and digital health. We are a well-funded and rapidly growing company with a clear vision to revolutionize sleep medicine through AI, continuously innovating to provide cutting-edge solutions for improved patient care.

Related Companies

Suggest an Edit →